KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Prepaid Assets (2016 - 2025)

West Pharmaceutical Services' Prepaid Assets history spans 17 years, with the latest figure at $131.8 million for Q3 2025.

  • For Q3 2025, Prepaid Assets fell 1.79% year-over-year to $131.8 million; the TTM value through Sep 2025 reached $131.8 million, down 1.79%, while the annual FY2024 figure was $124.0 million, 8.69% down from the prior year.
  • Prepaid Assets for Q3 2025 was $131.8 million at West Pharmaceutical Services, down from $167.7 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $167.7 million in Q2 2025 and bottomed at $67.4 million in Q1 2021.
  • The 5-year median for Prepaid Assets is $112.6 million (2022), against an average of $113.8 million.
  • The largest annual shift saw Prepaid Assets skyrocketed 117.05% in 2021 before it fell 16.43% in 2023.
  • A 5-year view of Prepaid Assets shows it stood at $112.0 million in 2021, then dropped by 8.04% to $103.0 million in 2022, then surged by 31.84% to $135.8 million in 2023, then decreased by 8.69% to $124.0 million in 2024, then increased by 6.29% to $131.8 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Prepaid Assets are $131.8 million (Q3 2025), $167.7 million (Q2 2025), and $121.0 million (Q1 2025).